Products - Oesophageal cancer | Topic | NICE

Showing 8 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC